Suppr超能文献

病因对新生血管性青光眼手术结局的影响。

The influence of etiology on surgical outcomes in neovascular glaucoma.

机构信息

Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, 900 NW 17th Street, Miami, FL, 33136, USA.

University of California San Francisco, San Francisco, CA, USA.

出版信息

BMC Ophthalmol. 2021 Dec 20;21(1):440. doi: 10.1186/s12886-021-02212-x.

Abstract

BACKGROUND

The authors sought to evaluate visual outcomes in patients with varying etiologies of neovascular glaucoma (NVG), who were treated with glaucoma drainage devices (GDD).

METHODS

This was a retrospective case series of patients at a large academic teaching institution who had surgical intervention for neovascular glaucoma between September 2011 and May 2019. Eyes were included if there was documented neovascularization of the iris/angle with an intraocular pressure (IOP) > 21 mmHg at presentation. Eyes must also have been treated with surgical intervention that included a GDD. Primary outcome measure was visual acuity at the 1-year post-operative visit. Secondary outcome measure was qualified success after surgery defined by: pressure criteria (5 mmHg < IOP ≤ 21 mmHg), no re-operation for elevated IOP, and no loss of LP vision.

RESULTS

One hundred twenty eyes met inclusion criteria. 61.7% had an etiology of proliferative diabetic retinopathy (PDR), 23.3% had retinal vein occlusions (RVO), and the remaining 15.0% suffered from other etiologies. Of patients treated with GDD, eyes with PDR had better vision compared to eyes with RVO at final evaluation (p = 0.041). There was a statistically significant difference (p = 0.027) in the mean number of glaucoma medications with Ahmed eyes (n = 70) requiring 1.9 medications and Baerveldt eyes (n = 46) requiring 1.3 medications at final evaluation.

CONCLUSIONS

In our study, many patients with NVG achieved meaningful vision, as defined by World Health Organization (WHO) guidelines, and IOP control after GDD. Outcomes differed between patients with PDR and RVO in favor of the PDR group. Different GDD devices had similar performance profiles for VA and IOP outcomes. Direct prospective comparison of Baerveldt, Ahmed, and cyclophotocoagulation represents the next phase of discovery.

摘要

背景

本研究旨在评估不同病因新生血管性青光眼(NVG)患者接受青光眼引流装置(GDD)治疗后的视力结局。

方法

本研究为单中心回顾性病例系列研究,纳入 2011 年 9 月至 2019 年 5 月期间于某大型教学医院因 NVG 接受手术治疗的患者。纳入标准为:虹膜/房角新生血管伴有初次就诊时眼压(IOP)>21mmHg;接受包括 GDD 在内的手术干预。主要结局指标为术后 1 年的视力。次要结局指标为术后定义的合格成功,包括:眼压标准(5mmHg<IOP≤21mmHg)、无因眼压升高而再次手术、无 LP 视力丧失。

结果

共纳入 120 只眼。61.7%的患者病因是增生性糖尿病视网膜病变(PDR),23.3%是视网膜静脉阻塞(RVO),其余 15.0%的患者病因不明。接受 GDD 治疗的患者中,PDR 患者的最终视力优于 RVO 患者(p=0.041)。最终评估时,Ahmed 组(n=70)和 Baerveldt 组(n=46)的平均青光眼药物数量分别为 1.9 种和 1.3 种,两组之间存在统计学差异(p=0.027)。

结论

在本研究中,许多 NVG 患者通过 GDD 治疗实现了有意义的视力和眼压控制,符合世界卫生组织(WHO)的标准。PDR 患者的结局优于 RVO 患者。不同的 GDD 装置在视力和眼压结局方面的表现相似。贝伐单抗、 Ahmed 和睫状体光凝的直接前瞻性比较代表了下一阶段的研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7af/8690523/5c2eca40cd56/12886_2021_2212_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验